" class="no-js "lang="en-US"> Alzheimer's Archives - Medtech Alert
Monday, April 15, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease

BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]

Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial

Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient […]

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain

Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]

Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases

Therini Bio, a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and […]

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia

Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]

BioArctic: Lecanemab Receives Priority Review Status in Japan

BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]

Eisai Submits Marketing Autherization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai and Biogen have announced that Eisai has submitted a marketing authorization application (MAA) for […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more